Avelumab and Merkel Cell Carcinoma: Examining Causation in Occupational Exposure

Legacy of General Health and Science Information

The legacy of general health and science information has long emphasized broad preventive care and the communication of risks associated with lifestyle, environment, and medical interventions. In mass production settings, this heritage translates into a foundational awareness of occupational hazards, where exposure to chemicals, biologics, or pharmaceuticals is systematically evaluated. Within this framework, the transition from general health literacy to specific occupational exposure concerns becomes critical. For instance, the therapeutic use of Avelumab, a monoclonal antibody approved for certain cancers, introduces a nuanced question in occupational health: whether exposure to this agent—through manufacturing, handling, or administration—could be associated with the development of Merkel Cell Carcinoma. This pivot requires moving beyond patient-centered risk communication to consider the implications for workers who may encounter Avelumab in production or clinical environments.

Bridge from General Health to Occupational Exposure

The bridge concept here is the shift from understanding Avelumab as a treatment to evaluating it as a potential occupational exposure, where causation must be examined without conflating therapeutic benefit with workplace risk. This transition underscores the need for rigorous exposure assessment and epidemiological monitoring in mass production contexts, ensuring that legacy health principles are adapted to emerging occupational scenarios.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus, and the incidence rate is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). MCC is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis is based on histopathological and immunohistochemical evaluation of skin lesions, which typically present as rapidly growing, painless, firm nodules on sun-exposed areas.

Avelumab Pharmacology and Reported Adverse Effects

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor and is approved in the USA, EU, and Japan for the treatment of metastatic MCC, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the phase II JAVELIN Merkel 200 trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcaemia secondary to reactivation of sarcoidosis, which can be managed with corticosteroids while continuing avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other adverse effects are consistent with those of PD-1/PD-L1 inhibitors, including fatigue, rash, and endocrine disorders.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The evidence does not support a causal relationship wherein avelumab induces or causes de novo Merkel cell carcinoma. Instead, avelumab is a therapeutic agent specifically approved for treating metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug works by blocking PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells, including MCC cells. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, a subset of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, with approximately 50% experiencing disease progression (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In such cases, combination therapy with ipilimumab plus nivolumab has shown activity in avelumab-refractory MCC, with three out of five patients responding according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG also reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Adequacy of Warnings and Risk Context

The evidence indicates that avelumab is approved for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events. However, the evidence does not suggest that avelumab causes MCC. Rather, it is a treatment for the disease. Warnings appropriately focus on the risk of irAEs, such as sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/), rather than on causation of MCC.

Causation Considerations for Affected Patients

For patients with MCC who are treated with avelumab, the primary causation consideration is whether the drug contributed to disease progression or lack of response. The evidence shows that approximately 50% of patients with advanced MCC progress on immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/). In avelumab-refractory cases, subsequent treatment with ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/). There is no evidence that avelumab causes MCC; instead, it is a standard therapy for the condition.

Timeline Between Exposure and Documented Harm

The timeline between avelumab exposure and harm is relevant to adverse events, not to causation of MCC. Immune-related adverse events, such as hypercalcaemia from sarcoidosis reactivation, can occur during treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline of progression is variable and depends on individual tumor biology and prior treatments. The JAVELIN Merkel 200 trial demonstrated responses in approximately one-third of patients, indicating that many patients derive benefit without harm (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Conclusion

Based on the available evidence, avelumab does not cause Merkel cell carcinoma. It is an approved therapeutic agent for the treatment of metastatic MCC. The drug is associated with immune-related adverse events, but there is no mechanistic or clinical evidence linking avelumab to the induction of MCC. Patients who experience progression on avelumab may have refractory disease, for which alternative immunotherapies exist.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel cell carcinoma?

No, Avelumab does not cause Merkel cell carcinoma. It is an FDA-approved treatment for metastatic Merkel cell carcinoma. The drug works by blocking PD-L1 to enhance the immune response against cancer cells. There is no evidence linking Avelumab to the development of MCC.

What are the risks of Avelumab exposure in occupational settings?

Occupational exposure to Avelumab may occur during manufacturing or handling. While Avelumab is not known to cause cancer, it can cause immune-related adverse events such as fatigue, rash, and endocrine disorders. Proper safety protocols should be followed to minimize exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.